Researchers have identified a gene that they reported was linked to a 1.5 times-higher likelihood of suffering from Alzheimer’s disease.
The latest research added that ADAMTS2 was the most significantly overexpressed gene in the brains of African American individuals with confirmed Alzheimer’s disease compared to those without.
Alzheimer’s disease is a looming plague in America as the US population skews older by the year.
Age is the most critical risk factor for Alzheimer’s disease.
The consistency across study populations indicated that these 65 genes are part of a core mechanism of Alzheimer’s disease, common across ancestral backgrounds.
According to research, there is a gene that increases the risk of developing Alzheimer’s disease by 1 in 5 times.
The ADAMTS2 gene was identified in brain tissue from patients with autopsy-confirmed Alzheimer’s disease by Boston University researchers in the first extensive study of the disease’s effects on African American donors’ brains.
Collagen formation, which aids in giving tissues structure, depends on ADAMTS2. Disorders that affect the body’s connective tissues are strongly associated with overexpression of the gene.
Neurodevelopment has also been linked to it. Particularly in the growing brain, specific collagen types create a structural scaffold. This vital structure is built and organized by ADAMTS2 processing collagen; if this process is disrupted, it may result in malfunctioning brain circuits.
According to the most recent study, the gene that was most markedly overexpressed in the brains of African Americans with confirmed Alzheimer’s disease relative to those without was ADAMTS2.
Reelin is one of its primary targets in the brain. Reelin is an essential protein for healthy brain development that supports cognitive function.
Reelin generally limits the development of amyloid plaque and decreases the formation of tau tangles, two characteristics thought to be indicative of Alzheimer’s disease. Reelin’s protective role, however, may be compromised by ADAMTS2.
This protective mechanism is upset by overactive ADAMTS2, which increases Tau and amyloid accumulation, which causes cognitive decline.
iframes are not supported by your browser.
These discoveries may pave the way for novel, focused genetic therapies that block or inhibit the ADAMTS2 protein. A medication that targets ADAMTS2 may benefit a wide range of individuals because the effect is the same for people of different ancestries.
Even in those with early indications of the disease in their brains, lowering ADAMTS2 activity may be a way to stop symptoms from appearing.
The study’s design also has an impact. The majority of genetic research has historically been conducted on individuals with European or White ancestry. The most recent research guarantees that future Alzheimer’s treatments and diagnostic tools will also be effective for Black Americans, an understudied population.
As the US population gets older every year, Alzheimer’s disease is becoming a serious problem in the country.
The percentage of people 65 and older increased from about 13 percent in 2010 to over 17 percent in 2022, and projections indicate that by 2030, it may account for almost 21 percent of the total population.
When it comes to Alzheimer’s disease, age is the biggest risk factor. After age 65, the chance of getting the disease doubles roughly every five years, which supports predictions that the number of cases will increase from the current 7 million to almost 14 million by 2060.
Donated brain tissue from 212 African Americans—82 of whom were cognitively healthy and 125 of whom had been diagnosed with Alzheimer’s—was included in the study’s sample.
To better understand the gene’s behavior in various demographics, researchers compared that cohort with another study that included individuals of European descent.
There are no iframes supported by your browser.
This study’s most important finding is consistent with the findings of the independent study on White participants, despite the fact that it only included Black participants.
“To our knowledge, this is the first time in similarly designed AD genetics studies that the most significant finding was the same in both white and African Americans,” stated Dr. Lindsay Farrer, corresponding author and the school’s chief of biomedical genetics. “.”.
The prefrontal cortex, a region that is particularly impacted by Alzheimer’s, provided the tissue from which scientists were able to visualize each gene and its activity level.
Additionally, genes with significantly different expression levels in Alzheimer’s cases and controls were found.
The main finding was that ADAMTS2 was the gene with the greatest overexpression in Alzheimer’s cases, with expression levels 1 point52 times greater than those in controls.
The importance of the same gene across ancestries was confirmed when it was a top-ranked hit in a different study’s computer analysis on a cohort with a preponderance of White/European ancestry.
Between the African American and European Ancestry study groups, the researchers found 65 genes that exhibited consistent behavior.
Compared to healthy controls, Alzheimer’s patients had genes that were either markedly overexpressed or underexpressed in this shared set.
Importantly, the direction of change was the same in both populations; genes that appeared in one group also appeared in the other, and genes that were suppressed appeared in both.
According to the study populations’ consistency, these 65 genes are a part of a fundamental mechanism of Alzheimer’s disease that is shared by people from different ancestral backgrounds.
The Alzheimer’s Association’s journal, Alzheimer’s and Dementia, published their findings.
In addition to ensuring that predictions based on genetic and [genomic] data are accurate in this population, the researchers came to the conclusion that “including [African American] participants in AD research is important because it has the potential to lead to new and important advances in knowledge about AD risk that will benefit everyone.”. “.”.
